Dengue virus (DENV) replication is known to prevent maturation of infected dendritic cells (DCs) thereby impeding the development of adequate immunity. During secondary DENV infection, dengue-specific antibodies can suppress DENV replication in immature DCs (immDCs), however how dengue-antibody complexes (DENV-IC) influence the phenotype of DCs remains elusive. Here, we evaluated the maturation state and cytokine profile of immDCs exposed to DENV-ICs. Indeed, DENV infection of immDCs in the absence of antibodies was hallmarked by blunted upregulation of CD83, CD86 and the major histocompatibility complex molecule HLA-DR. In contrast, DENV infection in the presence of neutralizing antibodies triggered full DC maturation and induced a balanced inflammatory cytokine response. Moreover, DENV infection under non-neutralizing conditions prompted upregulation of CD83 and CD86 but not HLA-DR, and triggered production of proinflammatory cytokines. The effect of DENV-IC was found to be dependent on the engagement of FcgRIIa. Altogether, our data show that the presence of DENV-IC alters the phenotype and cytokine profile of DCs.
Dengue disease is the most prevalent mosquito-borne viral disease, with approximately 400 million infections per year worldwide (Bhatt et al., 2013) . The disease is caused by infection with any of the four serotypes of dengue virus (DENV1-4). Primary infections are often asymptomatic and provide life-long protection against homotypic reinfection yet short-term (1-3 years) protection against heterotypic reinfections (WHO, 1997; Reich et al., 2013) . Strikingly, after the cross-protective period, individuals reinfected with a heterologous virus serotype are at risk of developing severe disease (Halstead, 2007) . Severe disease is also seen during primary infections in infants with low titres of circulating maternal dengue antibodies (Kliks et al., 1988; Simmons et al., 2007; Hause et al., 2015) . Clearly, antibodies play an important role in the outcome of DENV infection. Indeed, in vitro and in vivo studies demonstrated that DENV infectivity depends on the concentrations and/ or avidity of antibodies present during infection. DENV infection is contained in the presence of neutralizing antibody titres (Endy et al., 2004; van der Schaar et al., 2009; de Alwis et al., 2011) . At non-neutralizing antibody concentrations, however, enhanced infection of immune cells [antibody-dependent enhancement (ADE)] is seen due to viral entry via Fcg receptors (FcgR) (Rodrigo et al., 2006; Modhiran et al., 2010; Moi et al., 2010; Rodenhuis-Zybert et al., 2010) .
Dendritic cells (DCs) are the front line of defence against invading pathogens (Lutz & Schuler, 2002) . Upon antigen recognition, immature DCs (immDCs) acquire a mature phenotype (matDCs) characterized by high surface expression of co-stimulatory molecules, major histocompatibility complex II molecules (HLA-DR) and secretion of pro-and anti-inflammatory cytokines (Cella et al., 1997; Banchereau & Steinman, 1998) . Activation of DCs is crucial for shaping the innate responses and initiation of adaptive immunity (Dudek et al., 2013) . However, DCs also represent an important target for DENV replication during primary and secondary infections (Wu et al., 2000; Marovich et al., 2001; Schmid & Harris, 2014) . Indeed, in the absence of antibodies (direct infection), DENV not only efficiently infects immDCs (Boonnak et al., 2008; Nightingale et al., 2008) but is also able to blunt their maturation (Munoz-Jordan et al., 2003; Munoz-Jordan, 2010; Rodriguez-Madoz et al., 2010a; 2010b; Chang et al., 2012) . High titres of DENV-specific antibodies are capable of neutralizing DENV infection in immDCs (Boonnak et al., 2008) . In the presence of non-neutralizing antibody concentrations however, immDCs may support ADE of DENV infection (Boonnak et al., 2008; Dejnirattisai et al., 2011) . Remarkably, to date, little is known of how DENV-specific antibodies influence the activation of immDCs following DENV infection.
In this study, we evaluated the effect of DENV-specific antibodies on immDC activation. ImmDCs were generated from human monocytes isolated from buffy coats obtained from healthy, anonymous volunteers (Sanquin Bloodbank) and processed in line with the Declaration of Helsinki. Briefly, human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats by centrifugation using Ficoll-Paque Plus (GE Healthcare). Monocytes were isolated from PBMCs by gelatin adherence as previously described (Miller et al., 2008) and allowed to differentiate into immDCs by culturing at 37 C in complete RPMI medium (CM) with 20 % foetal bovine serum (FBS), 500 U ml À1 recombinant granulocyte macrophage colony-stimulating factor (rGM-CSF) and 250 U ml À1 recombinant interleukin-4 (IL-4; both from Prospec-Tany). Three-quarters of the culture medium was replaced every second day for six days to generate immDCs. After six days of culture, the phenotype of the cells was characterized as Lin-1 neg , HLA-DR pos and CD11c pos (Fig.  S1A , available in the online Supplementary Material), thus confirming the differentiation of monocytes into immDCs (Boonnak et al., 2008) . To generate matDCs that would serve as a positive control in our experiments, immDCs were stimulated on day 6 with MCM mimic containing 15 µg ml À1 recombinant IL-6500 ng ml À1 recombinant IL-1b, 500 ng ml À1 TNF-a and 100 µg ml À1 prostaglandin E2 (all from Bio Connect), as described in Boonnak et al., 2008 . At 24 h poststimulation, DCs showed increased expression of CD40, CD83, CD86 and HLA-DR compared to non-stimulated cells, which confirms the inherent capacity of our immDCs to mature (Fig. S1B) .
First, we analysed the permissiveness of immDCs to DENV-2 infection. DENV-2 strain 16681 was propagated in Aedes albopictus cell line C6/36, as described previously (Rodenhuis- Zybert et al., 2010) . The infectivity of DENV was determined by measuring the number of plaque-forming units (p.f.u.) by plaque assay (PA) on BHK-15 cells and the number of genome-equivalent copies (GEc) by quantitative RT-PCR (qRT-PCR), as described previously (van der Schaar et al., 2007; Zybert et al., 2008) . The cells were infected with DENV at a multiplicity of infection (m.o.i.) of 0.1, 1 or 10 at 37 C. At 2 hpi the inoculum was removed and cells were washed and cultured in fresh CM for another 22-24 h. At 24-26 hpi, cells and supernatants were harvested and separated by lowspeed centrifugation (5 min, 250 g). The percentage of DENV-positive cells was evaluated by flow cytometry using the DENV-2 envelope (E)-specific antibody 3H5 (Millipore) followed by a secondary anti-mouse Alexa-647-labelled antibody (Fig. 1a) . As expected, the infection rate was found to be m.o.i.-dependent, with the percentage of DENV E-positive cells varying among the donors. Progeny virus production was measured in the cell-free supernatants by plaque assay and qRT-PCR to obtain both p.f.u. and GEc titres (Fig. 1b) . In agreement with previous reports (Boonnak et al., 2008 (Boonnak et al., , 2011 , immDCs are highly permissive to DENV-2 replication.
To test the effect of antibodies on the permissiveness of immDCs to DENV-2, immDCs were infected at an m.o.i. of 1 with DENV-2 alone (direct infection) or DENV-2 immunecomplexes (DENV-IC). To generate DENV-IC, the virus was pre-incubated for 1 h at 37 C with 10-fold sequential dilutions of DENV-2-immune serum in a 1 : 1 volume ratio. In all experiments, two distinct convalescent DENV-2 immune sera [kindly provided by G. Comach (Biomed-UC, Lardidev, Maracay, Venezuela) and T. Kochel (U.S. Naval Medical Research Center Detachment, Lima, Peru)] were used as a source of polyclonal antibodies. The capacity of the sera to neutralize and enhance the DENV infection was previously confirmed in macrophage cell lines, human PBMCs and matDCs (Rodenhuis-Zybert et al., 2010, and unpublished results). The DENV-immune sera used exhibited potent neutralizing activity and inhibited DENV-2 infection at dilutions of 10 À2 -10 À6 for three distinct donors ( Fig. S2 ; data for 10 À3 dilution are shown in Fig. 1c, d ). The p.f.u. and GEc titres were below the detection limit (20 p.f.u. ml À1 and 400 GEc ml
À1
, respectively) following infection with DENV pre-opsonized with 10 À3 diluted serum (Fig. 1d) . Therefore, we used this serum dilution for neutralization conditions (Neutr). As expected, pre-incubation of DENV-2 with higher dilutions of the serum ( Fig. S2 ; data for 10 dilutions is shown in Fig. 1 ) recovered DENV infectivity to the levels of direct infection, as evidenced by flow cytometric analysis (Fig. 1c) as well as DENV p.f.u. and GEc titres in the cell supernatants (Fig. 1d) . Hence, 10 À8 serum dilution was used for non-neutralizing conditions (Non-neutr) in subsequent experiments. Importantly, in line with a previous report (Boonnak et al., 2008) , none of the serum dilutions was able to enhance DENV infection in immDCs (Fig. S2 ).
The effect of direct DENV infection on the maturation of immDCs has been studied previously (Libraty et al., 2001; Navarro-Sanchez et al., 2005; Palmer et al., 2005; Nightingale et al., 2008Boonnak et al., 2008 Sun et al., 2009 ), yet the effect of DENV-ICs on DCs remains unknown. To assess this, we next evaluated the surface expression of the DC maturation markers CD83, CD86 and HLA-DR 24 hpi following exposure of the cells to direct, UV-inactivated virus and non-neutralizing and neutralizing DENV infection conditions. Cells were harvested 24 hpi, placed into cytometry tubes and treated with FcRs blocking buffer (True Stain FcX; Biolegend) for 10 min at room temperature. Subsequently, the cells were washed in staining medium [EDTA, saponin (both from Sigma) and 2 % FBS]. Cell viability was evaluated using a LIVE/DEAD Fixable Dead Cell Stain Kit (Invitrogen). Phenotyping of the cells with a panel of DC markers, and intracellular DENV staining, were performed as described previously (van der Schaar et al., 2008; Richter et al., 2014) . Mock-infected (with or without the addition of neutralizing/non-neutralizing DENV-immune serum) and MCM mimic-stimulated cells (matDCs) were added as negative and positive controls, respectively. Figure. 2 illustrates the effects of different infection conditions on the levels of CD83, CD86 and HLA-DR compared to matched mock infections. Expression of CD40 was upregulated during all infection conditions (data not shown). In line with the above-mentioned studies, direct DENV infection did not promote significant upregulation of the maturation markers. Exposure of cells to UV-inactivated DENV-2 (Direct UVi, complete inactivation confirmed by PA) led to a modest increase in expression levels of CD83 and CD86, but had no effect on HLA-DR. Interestingly, exposure of cells to DENV at neutralizing serum concentrations triggered a significant increase in the expression of CD83, CD86 and HLA-DR when compared to direct infection condition. In fact, the expression level of the maturation markers found in DCs infected at neutralizing conditions was either higher (P>0.1 for CD86) or comparable to that of matDCs (Fig. 2) . The observed upregulation was not solely due to the blockage of DENV replication, as expression of CD83 and HLA-DR following exposure to UV-inactivated DENV were significantly lower (Fig 2) . Furthermore, DENV infection at non-neutralizing conditions also led to an increase in the expression pattern of the maturation markers (with P<0.1 for CD86) as compared to direct infection. Together, these results imply that the presence of DENV-IC promoted the maturation capacity of DCs.
Subsequently, we examined whether differences in the expression level of DC markers translated to a particular cytokine expression profile. To this end, we evaluated the levels of pro-(IL-6, TNF-a) and anti-inflammatory cytokines (IL-10, IL-4) in the supernatants of DCs infected under the conditions as described above (Fig. 3a) . In line with the lack of DC maturation, direct infection did not significantly alter the levels of the aforementioned cytokines when compared to mock infection. Importantly, when immDCs were exposed to neutralizing DENV-IC, the cells secreted significantly higher amounts of IL-6, TNF-a, IL-4 and IL-10 when compared to direct infection. In line with the data obtained for surface markers, addition of the neutralizing serum alone (Fig. 3b) , as well as direct UVi (data not shown), did not trigger significant changes in the cytokine response. Taken together, the observed increase following infection in the presence of serum was likely due to the presence of DENV-IC. This notion is further supported by the observation that non-neutralizing DENV-infection conditions resulted in higher, albeit variable between the donors, levels of IL-6, IL-4 and TNF-a than those induced by the direct infection (Fig. 3a) . Interestingly, it has recently been reported that induction of pro-inflammatory cytokines following immune-complex stimulation depends mainly on FcgRIIa (Vogelpoel et al., 2014) . Ligation of FcgRIIa is also required for the production of IL-6 and TNF-a following infection of matDCs under ADE conditions (Boonnak et al., 2008) . To assess the role of FcgRIIa in the activation of immDCs in the context of DENV infection, we pre-treated the immDCs with for 30 min with 5 mg ml À1 of FcgRIIablocking antibody, clone IV.3 (Stem Cell). Figure. 3(b, c) shows that blocking of FcgRIIa had no effect on the levels of cytokines under the condition of mock infection. However, it did prevent the production of cytokines during infection in the presence of neutralizing (Fig. 3b) and nonneutralizing (Fig. 3c ) serum concentrations. Thus, FcgRIIa ligation was responsible for the production of IL-6 and TNF-a following infection with DENV-IC. Of note, blocking of FcgRIIa had no effect on the neutralizing capacity of the antibodies or on the level of infection at non-neutralizing conditions (Fig. S3) .
In summary, our data demonstrate that the presence of DENV-IC triggers distinct DC phenotypes and cytokine profiles.
The main role of DCs is to sense, process and present antigens of invading pathogens to cells of the adaptive immune system (Banchereau & Steinman, 1998) . Viruses such as HIV-1, measles virus, vaccinia virus and DENV target DCs for replication (Wu et al., 2000; Ho et al., 2001; Marovich et al., 2001; de Witte et al., 2006; Boonnak et al., 2008; Liu et al., 2008; Nightingale et al., 2008; Dejnirattisai et al., 2011; Rinaldo, 2013) . Given the pivotal role of DCs in promoting adaptive immune responses, it is not surprising that many viruses impair the ability of infected DCs to initiate adaptive immunity (Lilley & Ploegh, 2005; Oreshkova et al., 2015) . Indeed, several studies have shown that DC maturation is blunted following DENV infection (Munoz-Jordan et al., 2003; Palmer et al., 2005; Rodriguez-Madoz et al., 2010a; 2010b; Chang et al., 2012) . In agreement with this, we found that DENV replication impedes DC maturation. Although not tested here, a previous study has shown that DENV infection in DCs impairs their antigen-presenting cell function (Palmer et al., 2005) . Indeed, clinical data show that antigen-presenting cells in patients suffering from acute DV infections are unable to stimulate Tcell responses to mitogens and DV antigens (Mathew et al., 1999) . Our data suggest that the presence of DENV-specific antibodies may exert distinct immunomodulatory effects in immDCs during secondary infection. At conditions of antibody-mediated virus neutralization, the expression of HLA-DR, CD83 and CD86 is upregulated to levels similar to mockinfected matDCs. Indeed, binding of ICs to FcRs on DCs is known to trigger phagocytosis, presentation of antigenic peptides on MHC class I and class II molecules and, depending on the FcR, differential cytokine production (Nimmerjahn & Ravetch, 2008; den Dunnen et al., 2012; Vogelpoel et al., 2014) . In line with this, we observed increased production of pro-inflammatory (IL-6 and TNF-a) and anti-inflammatory (IL-4 and IL-10) cytokines under conditions of DENV neutralization.
Exposure of immDCs to DENV-ICs at non-neutralizing conditions triggered a significant increase of CD83 and CD86 but did not alter the expression patterns of the HLA-DR. Moreover, TNF-a, IL-6 and IL-4 but not IL-10 were released under this condition. The presence of IL-4 is known to inhibit IL-10 production by DCs (Yao et al., 2005) . It is possible that the lack of IL-10 production is due to the significantly elevated levels of IL-4 released from DCs exposed to non-neutralizing conditions. Notably, balanced levels of TNF-a and IL-10 have been shown to be important for controlling inflammatory responses (van der Poll et al., 1995; Gudmundsson et al., 1998) . Thus it is tempting to speculate that this might be yet another mechanism contributing to a cytokine storm observed in the course of severe dengue (Costa et al., 2013; Pang et al., 2007; Soundravallyet al., 2014) . Mechanistically, the overall increase in cytokine production upon infection with non-neutralized DENV-ICs compared to direct infection suggests that FcRs-mediated infection triggers different downstream signalling pathways.
The presence of DENV-specific antibodies during DENV infection of DCs has consequences for the maturation of immDCs and subsequent cytokine responses. Our results corroborate earlier findings that DENV-2 can blunt the maturation and activation of exposed DCs. Importantly, we show that the presence of high concentrations of DENV-specific antibodies not only neutralizes DENV infection of immDCs but also rescues the ability of immDCs to mature and produce pro-and anti-inflammatory cytokines. On the other hand, infection in the presence of non-neutralizing antibody titres may induce a phenotype of DCs with reduced ability to present antigens while triggering mainly pro-inflammatory responses. Our data also showed that the ability of DCs to acquire these distinct phenotypes relies on FcgRIIa ligation. Further studies should investigate whether this partially impaired DC phenotype contributes to the aberrant T responses and exacerbation of inflammation seen during severe disease (Mangada & Rothman, 2005; Green & Rothman, 2006; Rothman, 2011) .
